retatrutide mechanism of action triple agonist glp-1 gip glucagon Beyond GLP-1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing Retatrutride is a triple-agonist peptide

Take a voice AI agent answering a customer support call

With tesamorelin, the most likely adverse events, according to the clinicians we know, are mild flu-like symptoms such as fatigue, headache, and nausea, but its also associated with an increased risk of cancer owing to its activity on growth hormone5 certainly more worrisome than the gastrointestinal problems linked to GLP-1 RAs

Like Semaglutide, Tirzepatide helps control blood sugar levels by influencing insulin production, leading to reduced weight gain and the fatigue associated with blood sugar spikes

At Begin Anew Med Spa, we believe that feeling your best starts with a proactive approach to well-being